AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.23 EPS

AtriCure (NASDAQ:ATRC) announced its quarterly earnings results on Tuesday. The medical device company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.23, FiscalAI reports. AtriCure had a return on equity of 2.34% and a net margin of 1.85%. The company had revenue of $154.45 million for the quarter, compared to the consensus estimate of $151.05 million.

Here are the key takeaways from AtriCure’s conference call:

• Strong third-quarter results: Revenue rose 15% year over year to $154.5 million, while net income reached $4.1 million and adjusted EBITDA increased 51% to $26.8 million.
• Growth was led by U.S. open ablation, appendage management, and pain management, including continued adoption of the EnCompass Clamp, AtriClip FLEX-Mini/PRO-Mini, and cryoSPHERE MAX. CryoXT revenue approached $1.5 million and surpassed 1,000 devices sold cumulatively.
• AtriCure remains on track to complete BoxX-NoAF enrollment before year-end, with initial clinical data expected in spring 2027; management views BoxX-NoAF and the ongoing LeAAPS study as significant future cardiac-surgery growth catalysts.
• Management cited continued headwinds in the U.S. hybrid ablation business and international markets, particularly European funding and reimbursement challenges; minimally invasive ablation sales declined during the quarter. The company also expects some gross-margin pressure from a full quarter of costs at its new manufacturing facility.
• Full-year 2026 revenue guidance was raised to approximately $606 million-$610 million, adjusted EBITDA guidance increased to $91 million-$94 million, and management said it remains confident in sustained profitable growth heading into 2027.

AtriCure Stock Up 0.9%

ATRC stock opened at $60.41 on Wednesday. AtriCure has a 52 week low of $25.36 and a 52 week high of $63.00. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The firm has a 50-day simple moving average of $56.03 and a 200-day simple moving average of $38.40. The stock has a market capitalization of $3.07 billion, a P/E ratio of 260.35 and a beta of 1.23.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus set a $65.00 target price on shares of AtriCure in a report on Thursday, September 17th. BTIG Research reissued a “buy” rating and set a $70.00 price target on shares of AtriCure in a report on Wednesday. Needham & Company LLC raised their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Wednesday, October 21st. Finally, UBS Group downgraded AtriCure from a “buy” rating to a “sell” rating in a research report on Wednesday, October 21st. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $56.40.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: For the quarter ended September 2026, AtriCure reported earnings of $0.17 per share and revenue of $154.45 million, beating analyst estimates of $151.05 million in revenue and consensus EPS estimates. The earnings improvement is notable compared with a loss of $0.01 per share a year earlier. AtriCure beats Q3 earnings and revenue estimates
• Positive Sentiment: Analysts raised their forecasts following the quarterly results, suggesting the earnings beat improved expectations for AtriCure’s outlook. Analysts boost forecasts after Q3 results
• Neutral Sentiment: AtriCure expects 2026 revenue of $606 million to $610 million, a range that spans the FactSet estimate of $606.2 million. This indicates expectations are broadly maintained, rather than signaling a clear outlook beat. AtriCure 2026 revenue outlook

Insider Buying and Selling at AtriCure

In other news, insider Karl S. Dahlquist sold 9,370 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the transaction, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Regina E. Groves sold 5,313 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the completion of the sale, the director owned 34,546 shares of the company’s stock, valued at $1,873,084.12. This trade represents a 13.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 30,622 shares of company stock valued at $1,626,003 over the last quarter. 4.00% of the stock is currently owned by insiders.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.